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Background: To evaluate the effect of variation of the Arg16Gly polymorphism of the β2-adrenergic receptor gene
on clinical response to salmeterol administered with fluticasone propionate in Chinese Han asthmatic patients.
Methods: Moderate persistent asthmatic patients (n = 62) currently receiving short-acting β2-agonists were administered
twice-daily therapy with salmeterol/fluticasone propionate 50/250 μg in a single inhaler for 12 weeks, followed by a
2-to-4-day run-out period. Using direct DNA sequencing, five single nucleotide polymorphisms (SNPs) in the promoter
and coding block regions of β2-adrenergic receptor gene were determined in 62 subjects and haplotypes were
combined.
Results: There was sustained and significant improvement (p < 0.001) over baseline in all measures of asthma
control in subjects receiving salmeterol and fluticasone, regardless of Arg16Gly genotype. However, there was no
significant difference in the improvement among three genotypes (p > 0.05). Responses to salmeterol did not
appear to be modified by haplotype pairs (p > 0.05). During the run-out period, all subjects had similar decreases in
measures of asthma control, with no differences between genotypes (p > 0.05).
Conclusions: Response to salmeterol does not vary with Arg16Gly polymorphisms after chronic dosing with
inhaled corticosteroids in Chinese Han asthmatic patients.
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Beta2-adrenergic receptor gene (ADRB2) is an intronless
gene located on chromosome 5q31.32 [1]. Screens of
ADRB2 have revealed at least 19 single nucleotide poly-
morphisms (SNP) within the coding and promoter
region, some of which might influence response to β2-
agonists [2-4]. The most prominent coding SNP is
characterized by substitution of glycine for arginine at
codon 16 (Arg16Gly), which occurs 38.3% in the Chinese
Han asthmatic patients [5].
Asthmatic patients who are homozygous for Arg/Arg
at the 16th amino acid position benefit less from treat-
ment with long-acting β2-agonists (LABA) and inhaled* Correspondence: qinyu@jscdc.cn
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unless otherwise stated.corticosteroids (ICS) than do those homozygous for Gly/
Gly in other asthmatic population [6].
To elucidate whether there is a genotype-dependent
influence of regular use of LABA combined with ICS in
Chinese Han asthmatic patients, we conducted a 12-week
trial of combined fluticasone propionate 250 μg and salme-
terol 50 μg in moderate persistent asthmatic patients, and
compared clinical outcomes according to the ADRB2
genotypes/haplotypes.Methods
Subjects aged 18 years or older and with a history of
persistent asthma of at least 6 months were included in
the study, as describe before [5]. The study protocols
were reviewed and approved by the Review Board of
Drum Tower Hospital Affiliated to Nanjing University
Medical School.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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nosed based on the Global Initiative for Asthma (GINA)
guidelines by Drum Tower Hospital Affiliated to Nanjing
University Medical School, and recruited in our study.
Eligible subjects entered a 2-week run-in period, and
all participants replaced their oral or inhaled SABAs
with albuterol prescribed as needed for the relief of
acute asthma symptoms. Peak expiratory flow (PEF),
albuterol use, asthma symptoms, and nighttime awak-
enings were recorded daily by the subjects on a diary
card. After the run-in period, participants meeting ran-
domization criteria entered the study and received fluti-
casone propionate/salmeterol (FSC), 250/50 μg diskus
twice daily. The criteria included the best FEV1 between
60% and 80% of predicted value; the best predose FEV1
within ±12% obtained at screening; 5 or more days re-
quiring albuterol use or a diary card asthma symptom
score of ≥2 on 3 or more days by using a 6-point scale
(0 = no symptoms, 5 = severe symptoms during the pre-
vious week). Sixty-two eligible asthmatic patients were
involved in the study. Baseline data for PEF, albuterol
use, asthma symptoms, and nighttime awakenings were
defined as the mean value over the 7 days before ran-
domization. Baseline FEV1 was defined as the ran-
domization visit FEV1 measurement. During the study,
FEV1 was measured at treatment weeks 1, 4, 8, and 12,
and 3 days after the treatment. After 12 weeks of treat-
ment with FSC, treatment was discontinued for 2 to
4 days while subjects continued to use albuterol as
needed and recorded daily symptoms and PEF on diary
cards. Baseline for this run-out period was defined as the
average of the last 7 days of the FSC treatment period.
Beta2-AR polymorphisms in positions −47, −20, 46, 79,
and 252 were determined by direct sequencing of PCR
products obtained with the following primers: 5′CAC
CAC AGC CGC TGA ATG AGG 3′and 5′GGC TTG
GTT CGT GAA GAA GTC 3′. The 710-bp PCR frag-
ments were purified with a commercial kit and sequenced
using a fluorescently labeled dye terminators technique
in an ABI Prism 310 capillary sequencer (PE Biosystems,
Foster City, CA).
Haplotypes were estimated from unphased genotypes
by using an extension of Clark’s algorithm [7]. The most
common five SNPs haplotypes were distinguished from
each other using only two SNPs (46 and 79), whichTable 1 Changes from baseline in the Arg16Gly genotype at
ADRB2marker Morning PEF (L/min) FEV1(L)
Arg16Gly genotype
ArgArg(n = 21) 114.4 ± 21.5 0.44 ± 0.09
ArgGly(n = 26) 103.3 ± 23.7 0.43 ± 0.07
GlyGly(n = 15) 100.3 ± 14.7 0.45 ± 0.11
No significant difference.coded for codon 16 and codon 27, respectively. The
genotype/haplotype frequencies for each polymorph-
ism were tested for deviation by the Hardy–Weinberg
equilibrium.
Data was entered and cleaned in Excel 2003. Variables
were presented as means ± standard deviations (SD), with
chi-square test for categorical variables and ANOVA
for continuous variables. Evaluation of the effect of
genotype/haplotypes on each clinical parameter was car-
ried out by ANOVA. All analyses were conducted in SPSS
13.0 statistical software (SPSS Inc., Chicago, IL, USA).
Results
There were no significant differences in demographic,
clinical and pulmonary function characteristics across
the Arg16Gly genotypes at baseline (p > 0.05).There
was sustained and significant improvement (p < 0.001)
compared with baseline values in all measurements
of asthma control in all Arg16Gly genotypes. However, the
changes of all measurements were not significantly differ-
ent across genotype subgroups (p > 0.05) (Table 1). No
significant differences were identified between haplotype
pairs and changes of all the measurements (Table 2). Dur-
ing the run-out phase, no differences were noted in any of
the clinical responses to FSC withdrawal across the geno-
types (Table 3).
Discussion
Our study showed that clinical response to the LABA
salmeterol did not differ among ADRB2 Arg16Gly SNPs
during chronic dosing in the presence of an ICS. Specif-
ically, there were sustained and quantitatively similar im-
provements in lung function, symptoms, and albuterol
use during chronic treatment, regardless of Arg16Gly
genotype. Although not powered to definitively evaluate
a haplotype effect, our haploype analysis supports the in-
dividual SNP results.
Drysdale et al. [2] showed the lowest response in
their 4/4 haplotype, corresponding to our Arg16Gln27/
Arg16Gln27 haplotype, with a total of 14 subjects as
opposed to the 24 in our analysis. Although we did not
measure all 13 possible SNPs, using the 5 SNPs at
position −47, −20, 46, 79, and 252, we were able to evalu-
ate the most frequent haplotypes corresponding to those
previously reported [2,8].the end of 12 weeks of treatment with FSC
Albuterol use (puffs/d) Asthma symptom score
−3.81 ± 1.94 −1.10 ± 0.78
−3.77 ± 1.95 −0.96 ± 0.53
−3.80 ± 1.86 −0.93 ± 0.59
Table 2 Changes from baseline among five haplotype pairs at the end of 12 weeks of treatment with FSC stratified by
haplotype pairs
Haplotype pair Morning PEF (L/min) FEV1(L) Albuterol use (puffs/d) Asthma symptom score
AC/AC 108.3 ± 25.1 0.46 ± 0.10 −3.50 ± 2.00 −0.79 ± 0.16
GC/GC 89.0 ± 18.5 0.41 ± 0.09 −3.57 ± 1.90 −1.00 ± 0.23
GC/GG 104.4 ± 31.1 0.49 ± 0.11 −4.60 ± 1.89 −1.20 ± 0.45
GC/AC 111.4 ± 28.1 0.42 ± 0.07 −3.85 ± 2.06 −1.05 ± 0.51
GG/AC 103.7 ± 27.9 0.45 ± 0.05 −4.33 ± 1.63 −1.17 ± 0.75
No significant difference.
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ings of Taylor et al. [9], who demonstrated no differ-
ential response in exacerbations or lung function in
subjects receiving salmeterol, regardless of genotype. Fur-
thermore, our results supported the finding of Bleecker
et al. [10] who suggested that Gly16Arg genotypes might
not be a genetic determinant of reduced responses to
chronic LABA therapy in the presence of ICS therapy
in subjects with asthma. In addition, a retrospective
study by Klotsman et al. [11] and a recent 6-month
double blind randomized study by Bleecker et al. [12]
revealed no genotype effect of ADRB2 on the combin-
ation therapy.
In contrast, Salmeterol or Corticosteroids (SOCS) trial
and Salmeterol +/−Inhaled Corticosteroid (SLIC) trials
demonstrated a genotypic-difference in LABA response
[13,14]. Genotypic analysis of the SOCS and SLIC co-
horts by Weschler [6] revealed that Arg16Arg had a
lower morning PEF than Gly16Gly during salmeterol
therapy. These results supported an ADRB2 genotype ef-
fect on responses to LABA therapy. Furthermore, two
retrospective studies showed an ADRB2 genotype effect
on response to therapy with the β2-agonists [15,16]. In
addition, our results were different from a Korean study
which suggested that the ADRB2 genotype may dictate
choice of treatment strategy [17,18].
The inconsistent results could be attributed to various
factors, including ethnic difference, sample size, differ-
ences in study design, asthma severity, and intrinsic activityTable 3 Differences between the last 7 days on treatment
and the run-out period stratified by genotype for subjects
previously treated with FSC
Genotype
Arg/Arg(n = 21) Arg/Gly(n = 26) Gly/Gly(n = 15)
Morning PEF (L/min) −38.2 ± 8.6 −24.2 ± 10.2 −34.3 ± 9.8
FEV1 (L) −0.09 ± 0.05 −0.10 ± 0.03 −0.10 ± 0.03
Total albuterol use 0.71 ± 0.23 0.69 ± 0.38 0.73 ± 0.28
Asthma symptom
score
0.43 ± 0.17 0.35 ± 0.19 0.33 ± 0.14
No significant difference.of the β2-agonist evaluated, linkage disequilibrium and
concomitant use of an ICS.
In our study, LABA treatment was combined with
ICS, therefore it is quite possible that the differences in
response to ICS among genotype groups could account
for the observed differences. However, this possibility
is quite unlikely, because all the study subjects used
the same regimen of ICS during the 2-week run-in,
and showed improvement in both FEV1 and PEF, with
no significant differences observed between genotype
groups.
There were some limitations in our study. In the
present study the observations did not eliminate com-
pletely a genetic interaction. In addition, the haplotype
analysis did not reveal any significant influence on re-
sponse, but the small sample size and the lack of ethnic
representation might limit these conclusions.
Conclusions
In summary, this study evaluating associations between
the polymorphic gene encoding for the β-agonist drug
target and responses to therapy with LABA showed that
response to salmeterol does not vary by ADRB2 geno-
types or haplotypes during chronic dosing in the pres-
ence of an ICS.
However, larger prospective clinical pharmacogenetic
studies are further needed to help elucidate this field.
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